A broad effect of ocrelizumab on the peripheral immune component in patients with early relapsing-remitting multiple sclerosis

被引：0
|
作者：
Garcia, A. [1 ]
Morille, J. [1 ]
Shah, S. [1 ]
Le Frere, F. [2 ]
Nicot, A. [1 ]
Berthelot, L. [1 ]
Wiertlewski, S. [1 ,2 ]
Gourraud, P. -A. [1 ,3 ]
Raposo, C. [4 ]
Bakdache, F. [4 ]
Buffels, R. [4 ]
Laplaud, D. -A. [1 ,2 ]
机构：
[1] Univ Nantes, CHU Nantes, INSERM, Ctr Rech Transplantat & Immunol,UMR 1064, Nantes, France
[2] CHU Nantes, Dept Neurol, CIC Neurol, Nantes, France
[3] CHU Nantes, INSERM, CIC 1413, Pole Hosp Univ 11 Sante Publ,Clin Donnees,ATIP Av, Nantes, France
[4] F Hoffmann La Roche Ltd, Basel, Switzerland
来源：
MULTIPLE SCLEROSIS JOURNAL | 2021年 / 27卷 / 2_SUPPL期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P701
引用
收藏
页码：593 / 594
页数：2
相关论文
共 50 条
  • [1] Ocrelizumab in Early-Stage Relapsing-Remitting Multiple Sclerosis
    Hartung, Hans-Peter
    Benedict, Ralph H. B.
    Berger, Thomas
    Bermel, Robert A.
    Brochet, Bruno
    Carroll, William M.
    Freedman, Mark S.
    Holmoy, Trygve
    Karabudak, Rana
    Nos, Carlos
    Patti, Francesco
    Perrin Ross, Amy
    Vanopdenbosch, Ludo
    Vollmer, Timothy
    Wuerfel, Jens
    Clinch, Susanne
    Kadner, Karen
    Kuenzel, Thomas
    Kulyk, Inessa
    Raposo, Catarina
    Thanei, Gian-Andrea
    Killestein, Joep
    NEUROLOGY, 2024, 103 (12)
  • [2] Ocrelizumab for the treatment of relapsing-remitting multiple sclerosis
    Menge, Til
    Dubey, Divyanshu
    Warnke, Clemens
    Hartung, Hans-Peter
    Stuve, Olaf
    EXPERT REVIEW OF NEUROTHERAPEUTICS, 2016, 16 (10) : 1131 - 1139
  • [3] Immune Profiling Reveals the T-Cell Effect of Ocrelizumab in Early Relapsing-Remitting Multiple Sclerosis
    Garcia, Alexandra
    Dugast, Emilie
    Shah, Sita
    Morille, Jeremy
    Lebrun-Frenay, Christine
    Thouvenot, Eric
    De Seze, Jerome
    Le Page, Emmanuelle
    Vukusic, Sandra
    Maurousset, Aude
    Berger, Eric
    Casez, Olivier
    Labauge, Pierre
    Ruet, Aurelie
    Raposo, Catarina
    Bakdache, Fabien
    Buffels, Regine
    Le Frere, Fabienne
    Nicot, Arnaud
    Wiertlewski, Sandrine
    Gourraud, Pierre-Antoine
    Berthelot, Laureline
    Laplaud, David
    NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION, 2023, 10 (03):
  • [4] Rituximab vs Ocrelizumab in Relapsing-Remitting Multiple Sclerosis
    Roos, Izanne
    Hughes, Stella
    McDonnell, Gavin
    Malpas, Charles B.
    Sharmin, Sifat
    Boz, Cavit
    Alroughani, Raed
    Ozakbas, Serkan
    Buzzard, Katherine
    Skibina, Olga
    van der Walt, Anneke
    Butzkueven, Helmut
    Lechner-Scott, Jeannette
    Kuhle, Jens
    Terzi, Murat
    Laureys, Guy
    Van Hijfte, Liesbeth
    John, Nevin
    Grammond, Pierre
    Grand'Maison, Francois
    Soysal, Aysun
    Jensen, Ana Voldsgaard
    Rasmussen, Peter Vestergaard
    Svendsen, Kristina Bacher
    Barzinji, Ismael
    Nielsen, Helle Hvilsted
    Sejbaek, Tobias
    Prakash, Sivagini
    Stilund, Morten Leif Munding
    Weglewski, Arkadiusz
    Issa, Nadia Mubder
    Kant, Matthias
    Sellebjerg, Finn
    Gray, Orla
    Magyari, Melinda
    Kalincik, Tomas
    MSBase Study Grp
    Danish MS Registry Study Grp
    JAMA NEUROLOGY, 2023, 80 (08) : 789 - 797
  • [5] Switching from natalizumab to ocrelizumab in patients with relapsing-remitting multiple sclerosis
    Van Lierop, Z.
    Toorop, A.
    Willemse, E.
    Strijbis, E.
    Kalkers, N.
    Moraal, B.
    Barkhof, F.
    Teunissen, C.
    Killestein, J.
    Van Kempen, Z.
    MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (3_SUPPL) : 310 - 311
  • [6] Ocrelizumab modifies circulating immune asset in relapsing-remitting multiple sclerosis subjects
    Abbadessa, Gianmarco
    Bruzzaniti, Sara
    Miele, Giuseppina
    Piemonte, Erica
    Signoriello, Elisabetta
    Lus, Giacomo
    Matarese, Giuseppe
    Galgani, Mario
    Bonavita, Simona
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2021, 429 : 21 - 21
  • [7] Evaluation of shorter infusion times with ocrelizumab in patients with relapsing-remitting multiple sclerosis
    Vollmer, Timothy
    Alvarez, Enrique
    Nair, Kavita
    Cohen, Jeffrey
    Boster, Aaron
    Masterman, Donna
    Pradhan, Ashish
    Musch, Bruno
    Ma, Xiaoye
    Pei, Jinglan
    Moss, Brandon
    Weinstock-Guttman, Bianca
    Bermel, Robert
    NEUROLOGY, 2019, 92 (15)
  • [8] Half-dose ocrelizumab in selected patients with relapsing-remitting multiple sclerosis
    Algahtani, Hussein
    Shirah, Bader
    Alqahtani, Abdulhadi
    Abdelghaffar, Nawal
    Makki, Samiah
    ACTA NEUROLOGICA BELGICA, 2024, 124 (01) : 303 - 306
  • [9] Real world experience with ocrelizumab in patiens with relapsing-remitting multiple sclerosis
    Lopez Ruiz, R.
    Dotor Garcia-Soto, J.
    Hiraldo, J. D. G.
    Ruiz-Pena, J. L.
    Paramo Camino, M. D.
    Ruiz De Arcos, M.
    Navarro Mascarell, G.
    Eichau Madueno, S.
    MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (3_SUPPL) : 301 - 301
  • [10] The comparative effectiveness of fingolimod, natalizumab, and ocrelizumab in relapsing-remitting multiple sclerosis
    Cavit Boz
    Serkan Ozakbas
    Murat Terzi
    Rana Karabudak
    Serhan Sevim
    Recai Turkoglu
    Aysun Soysal
    Belgin Petek Balcı
    Hüsnü Efendi
    Ömer Faruk Turan
    Nur Yüceyar
    Mehmet Fatih Yetkin
    Serap Zengin Karahan
    Meltem Demirkıran
    Sibel Guler
    Kadriye Agan
    Nefati Kıylıoğlu
    Cavid Baba
    Asli Tuncer
    Mesrure Köseoğlu
    Neurological Sciences, 2023, 44 : 2121 - 2129
12345